Successful Pregnancies for Rheumatology Patients: Navigating a New Era of Optimism

FORT LAUDERDALE, Fla. — A significant paradigm shift is underway in the management of rheumatic diseases during pregnancy. Recent insights, underscored at the 2026 Rheumatology Nurses Society annual conference, confirm a growing optimism: “Many rheumatic medications can be used with confidence in the pregnancy setting.” Dr. Cuoghi Edens, an associate professor of internal medicine and pediatrics at the University of Chicago, emphasized that “a large proportion of our rheumatology patients can have successful pregnancies.” This statement reflects years of accumulated research and clinical experience, offering profound hope to individuals living with chronic autoimmune conditions who aspire to build families.

Main Article: Empowering Family Planning in Rheumatic Disease

For too long, the prospect of pregnancy for women with rheumatic diseases was overshadowed by concern, often leading to difficult choices between managing their condition and fulfilling family aspirations. Conditions like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) present unique challenges during gestation, including potential disease flares, medication complexities, and risks to both maternal and fetal health. However, modern rheumatology has made remarkable strides, transforming what was once a landscape of apprehension into one of proactive management and successful outcomes.

The Crucial Role of Medication Safety

A cornerstone of this transformation is the advancements in understanding and utilizing medications safely during pregnancy. Historically, many powerful immunosuppressants and disease-modifying anti-rheumatic drugs (DMARDs) were either contraindicated or used with extreme caution due to fears of teratogenicity – the potential to cause birth defects. Today, rigorous studies and extensive registries have provided invaluable data, allowing clinicians to differentiate between truly harmful medications and those that can be continued or carefully adjusted.

• Biologic Therapies: Many biologics, particularly TNF inhibitors, have demonstrated reassuring safety profiles when continued through much of pregnancy, often with dose adjustments or discontinuation closer to term based on individual risk-benefit assessment. Their targeted action often minimizes systemic exposure to the fetus compared to older, broader immunosuppressants.
• Conventional DMARDs: While some, like methotrexate and leflunomide, remain strictly contraindicated, others such as hydroxychloroquine and sulfasalazine are widely recognized as safe and often crucial for maintaining disease control.
• Steroids: Low-dose corticosteroids can be used when necessary to control flares, with careful monitoring for maternal side effects like gestational diabetes or preeclampsia.

The key lies in a highly individualized approach, balancing optimal disease control to prevent flares – which themselves can pose significant risks to pregnancy – against potential medication risks. This nuanced understanding empowers both patients and their medical teams to make informed decisions.

Beyond Medications: The Importance of a Multidisciplinary Approach

Successful pregnancy in rheumatic disease extends far beyond medication management. It necessitates a coordinated, multidisciplinary effort involving:

• Rheumatologist: To manage the underlying disease activity and adjust therapies.
• High-Risk Obstetrician (Maternal-Fetal Medicine Specialist): To monitor maternal and fetal well-being, manage obstetric complications, and provide specialized care.
• Neonatologist: If there are concerns about preterm birth or specific neonatal issues.
• Other Specialists: Depending on specific organ involvement (e.g., nephrologists for lupus nephritis).
• Rheumatology Nurses and Educators: Providing crucial patient education, support, and coordination of care.

This collaborative framework ensures comprehensive monitoring, timely interventions, and consistent communication, vastly improving outcomes for both mother and baby.

Background: From Caution to Confidence – A Historical Shift

The journey to the current optimistic outlook has been a long one. For many decades, women with significant rheumatic diseases were often advised against pregnancy due to a confluence of factors:

• Unpredictable Disease Flares: Pregnancy was often seen as a trigger for disease exacerbations, particularly in conditions like lupus, posing serious risks to maternal health and increasing the likelihood of pregnancy complications such as miscarriage, preterm birth, and preeclampsia.
• Limited Safe Therapeutic Options: The pharmacopeia available was largely composed of drugs with known or suspected teratogenic effects, leaving clinicians with difficult choices between treating active disease and avoiding fetal harm. This often meant discontinuing essential medications, leading to flares.
• Lack of Robust Data: Historically, pregnant women were excluded from clinical trials, leading to a paucity of evidence-based guidance on medication safety. Decisions were often made based on anecdote or theoretical risks.
• Adverse Pregnancy Outcomes: Higher rates of prematurity, intrauterine growth restriction (IUGR), and stillbirths were observed, particularly in uncontrolled or severe cases, reinforcing the perception of high risk.

The past two decades have seen a concerted effort to gather prospective data, establish pregnancy registries, and conduct observational studies. This meticulous work has illuminated the natural course of rheumatic diseases in pregnancy, identified safer therapeutic windows, and clarified the risks associated with active disease versus carefully selected medications. This robust evidence base has been instrumental in shifting clinical practice and patient counseling from one of default caution to one of informed confidence.

Why It Matters: A Future of Empowered Choices and Improved Outcomes

The assertion that “most rheumatology patients can have successful pregnancies” is more than just a medical statement; it represents a profound leap forward in patient care and quality of life. This evolving understanding matters for several critical reasons:

1. Patient Empowerment and Quality of Life: It gives women living with chronic rheumatic conditions the autonomy and confidence to plan their families, rather than facing the heartbreaking choice between their health and their desire for children. It validates their aspirations and improves their overall well-being.
2. Improved Maternal and Fetal Outcomes: By enabling patients to maintain disease remission or low disease activity throughout pregnancy with safe medications, the risks of flares are significantly reduced. This, in turn, decreases the incidence of adverse maternal events (e.g., organ damage, severe hypertension) and improves fetal outcomes (e.g., reduced prematurity, higher birth weights, fewer developmental issues).
3. Enhanced Preconception Counseling: The positive outlook encourages earlier and more comprehensive preconception counseling. This crucial step allows rheumatologists and patients to discuss family planning, optimize disease control, review and adjust medications well in advance, and identify potential risks. This proactive approach is foundational to achieving successful pregnancies.
4. Advancement in Research and Education: The growing success stories fuel further research into safer therapies, better monitoring strategies, and personalized risk assessment tools. It also emphasizes the ongoing need for education for both healthcare providers and patients to stay abreast of the latest guidelines and best practices.
5. Challenging Stigma: This positive message helps to dismantle the stigma and fear often associated with chronic illness and pregnancy, promoting a more inclusive and supportive environment for patients.